Skip to main content
. 2020 Jan 21;9(2):e014248. doi: 10.1161/JAHA.119.014248

Figure 2.

Figure 2

Relative use of transcatheter aortic valve replacement (TAVR) in cancer vs noncancer. On comparing the cancer and noncancer groups, TAVR use was more evident in the cancer group (P<0.0001 for cancer vs noncancer, year 2015). TAVR use in cancer subtypes in 2015 included 21.8% prostate cancer, 19.6% breast cancer, 9.1% colon cancer, 6.4% lung cancer, and 43.1% other cancers.